Log in
NYSE:PKI

PerkinElmer Stock Forecast, Price & News

$118.20
-1.29 (-1.08 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$117.57
Now: $118.20
$120.28
50-Day Range
$112.01
MA: $117.73
$122.09
52-Week Range
$62.91
Now: $118.20
$123.21
Volume1.16 million shs
Average Volume896,278 shs
Market Capitalization$13.22 billion
P/E Ratio44.94
Dividend Yield0.23%
Beta1.36
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More
PerkinElmer logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$6.30 per share
Book Value$25.33 per share

Profitability

Net Income$227.56 million

Miscellaneous

Employees13,000
Market Cap$13.22 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$118.20
-1.29 (-1.08 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PerkinElmer (NYSE:PKI) Frequently Asked Questions

How has PerkinElmer's stock been impacted by COVID-19?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PKI stock has increased by 62.3% and is now trading at $118.20.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of PerkinElmer?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PerkinElmer
.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for PerkinElmer
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings results on Tuesday, July, 28th. The medical research company reported $1.57 EPS for the quarter, topping analysts' consensus estimates of $0.70 by $0.87. The medical research company had revenue of $811.91 million for the quarter, compared to the consensus estimate of $703.32 million. PerkinElmer had a return on equity of 18.40% and a net margin of 9.87%. The business's revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.00 earnings per share.
View PerkinElmer's earnings history
.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, July 23rd. Shareholders of record on Friday, October 16th will be paid a dividend of $0.07 per share on Friday, November 6th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date of this dividend is Thursday, October 15th.
View PerkinElmer's dividend history
.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its third quarter earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of $1.18-1.53 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.09. The company issued revenue guidance of $760-860 million, compared to the consensus revenue estimate of $751.41 million.

What price target have analysts set for PKI?

15 Wall Street analysts have issued twelve-month price objectives for PerkinElmer's stock. Their forecasts range from $45.00 to $139.00. On average, they anticipate PerkinElmer's share price to reach $95.13 in the next twelve months. This suggests that the stock has a possible downside of 19.5%.
View analysts' price targets for PerkinElmer
.

Are investors shorting PerkinElmer?

PerkinElmer saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,560,000 shares, an increase of 19.6% from the August 15th total of 2,140,000 shares. Based on an average daily trading volume, of 914,600 shares, the days-to-cover ratio is presently 2.8 days. Approximately 2.3% of the company's stock are sold short.
View PerkinElmer's Short Interest
.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Pfizer (PFE), CVS Health (CVS), Home Depot (HD), Johnson & Johnson (JNJ), Visa (V), Paypal (PYPL) and Abbott Laboratories (ABT).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.06%), King Luther Capital Management Corp (2.17%), Goldman Sachs Group Inc. (0.97%), Bank of New York Mellon Corp (0.83%), Charles Schwab Investment Management Inc. (0.75%) and Prudential PLC (0.59%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett and Prahlad R Singh.
View institutional ownership trends for PerkinElmer
.

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc., Vanguard Group Inc., First Trust Advisors LP, Robecosam AG, Charles Schwab Investment Management Inc., UBS Group AG, Sector Gamma AS, and SG Americas Securities LLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Joel S Goldberg, Pascale Witz, and Peter Barrett.
View insider buying and selling activity for PerkinElmer
.

Which major investors are buying PerkinElmer stock?

PKI stock was acquired by a variety of institutional investors in the last quarter, including Prudential PLC, Ceredex Value Advisors LLC, Goldman Sachs Group Inc., Tesco Pension Investment Ltd, Federated Hermes Inc., Bank of Nova Scotia, AQR Capital Management LLC, and State of Wisconsin Investment Board.
View insider buying and selling activity for PerkinElmer
.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $118.20.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $13.22 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis. PerkinElmer employs 13,000 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.